Literature DB >> 23380345

Pre-engraftment syndrome after unrelated cord blood transplantation: a predictor of engraftment and acute graft-versus-host disease.

Meerim Park1, Soo Hyun Lee, Young Ho Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn, Nak Gyun Chung, Bin Cho, Hack Ki Kim, Kyung Nam Koh, Ho Joon Im, Jong Jin Seo, Dong Kyun Han, Hee Jo Baek, Hoon Kook, Tai Ju Hwang, Eun Kyung Lee, Jeong Ok Hah, Yeon Jung Lim, Hyun Joo Jung, Jun Eun Park, Moon Ju Jang, So Young Chong, Doyeun Oh.   

Abstract

Pre-engraftment syndrome (PES) is poorly characterized, and its clinical significance and the prognostic impact after unrelated cord blood transplantation (CBT) are unclear. To address these issues, we retrospectively analyzed the incidence, risk factors, and clinical outcomes of PES in unrelated CBT recipients. Data of 381 patients who received unrelated CBT from 18 medical centers in Korea were reviewed. PES was defined as unexplained fever >38.3°C not associated with infection, and/or unexplained skin rash with or without evidence of fluid retention before neutrophil recovery. PES developed in 102 patients (26.8%) at a median of 7 days after CBT. Of these patients, 74 patients (72.5%) received intravenous corticosteroid at a median dose of 1 mg/kg/day, and of these, 95% showed clinical improvement. Risk factors for developing PES included low risk disease, myeloablative conditioning, graft-versus-host disease (GVHD) prophylaxis without methotrexate or corticosteroid, and >5.43 x 10(7)/kg infused nucleated cells. Absence of PES was one of the risk factors for graft failure in multivariate analysis. The cumulative incidence of grade II to grade IV acute GVHD by 100 days after CBT was higher in patients with PES than in those without PES (56.0% versus 34.4%, P < .01). PES was not associated with chronic GVHD, treatment-related mortality, relapse, or overall survival. PES seems to be common after CBT and may be associated with enhanced engraftment without significant morbidity.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23380345     DOI: 10.1016/j.bbmt.2013.01.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

1.  Engraftment Syndrome and Acute Graft-versus-Host Disease: A Meta-Analysis.

Authors:  Kittika Poonsombudlert; Jakrin Kewcharoen; Chattip Prueksapraopong; Nath Limpruttidham
Journal:  Hawaii J Health Soc Welf       Date:  2020-06-01

Review 2.  Engraftment syndrome: double-edged sword of hematopoietic cell transplants.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

Review 3.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

4.  Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.

Authors:  H-L Liu; Z-M Sun; L-Q Geng; X-B Wang; K-Y Ding; J Tong; B-L Tang; C-Y Zhou; W Yao; C-C Zheng; K-D Song; X-Y Zhu; W Wei; Y Wang
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

5.  Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Authors:  Lawrence Chang; David Frame; Thomas Braun; Erin Gatza; David A Hanauer; Shuang Zhao; John M Magenau; Kathryn Schultz; Hemasri Tokala; James L M Ferrara; John E Levine; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

6.  Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation.

Authors:  Kyle R Brownback; Steven Q Simpson; Joseph P McGuirk; Tara L Lin; Sunil Abhyankar; Siddhartha Ganguly; Omar S Aljitawi
Journal:  Ann Hematol       Date:  2013-12-18       Impact factor: 3.673

7.  Inpatient Management of Mucocutaneous GVHD.

Authors:  Toral Vaidya; Christian Menzer; Doris M Ponce; Alina Markova
Journal:  Curr Dermatol Rep       Date:  2019-11-11

8.  Comparative Study between Intravenous and Intraperitoneal Stem Cell Therapy in Amiodarone Induced Lung Injury in Rat.

Authors:  Maha Baligh Zickri; Sahar Gamal Aboul Fadl; Hala Gabr Metwally
Journal:  Int J Stem Cells       Date:  2014-05       Impact factor: 2.500

9.  Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients.

Authors:  Linlin Jin; Zimin Sun; Huilan Liu; Xiaoyu Zhu; Yonggang Zhou; Binqing Fu; Xiaohu Zheng; Kaidi Song; Baolin Tang; Yun Wu; Jiang Zhu; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  Nat Commun       Date:  2021-07-06       Impact factor: 14.919

10.  A proposal for improvement in the utilization rate of banked cord blood.

Authors:  Young-Ho Lee; Ji Yoon Kim; Yeung-Chul Mun; Hong Hoe Koo
Journal:  Blood Res       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.